Skip to main content

FGFR Biological Pathways Reviews

Videos

Vivek Subbiah, MD, Sarah Cannon Research Institute
Videos
12/12/2023
Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.
Vivek Subbiah, MD, discusses the management of adverse events associated with FGFR inhibitors for urothelial carcinoma and cholangiocarcinoma.
Vivek Subbiah, MD, discusses the...
12/12/2023
Oncology
Antoni Vilaseca, MD, Hospital Clínic de Barcelona
Videos
11/01/2023
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.
Antoni Vilaseca, MD, discusses...
11/01/2023
Oncology
Daniel DeAngelo, MD, PhD
Videos
08/28/2023
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD, presents data on the promising outcomes of pemigatinib, an FGFR1 inhibitor, among patients with myeloid lymphoid neoplasms, at the 2023 Great Debates & Updates in Hematologic Malignancies meeting.
Daniel DeAngelo, MD, PhD,...
08/28/2023
Oncology
Vivek Subbiah, MD, MD Anderson Cancer Center
Videos
04/11/2022
Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.
Vivek Subbiah, MD, University of Texas, shares updates of pemigatinib in the upcoming FIGHT-302 study and highlights how an FDA approval will benefit patients with CCA harboring an FGFR2 mutation.
Vivek Subbiah, MD, University of...
04/11/2022
Oncology
Vivek Subbiah, MD, MD Anderson Cancer Center
Videos
04/01/2022
Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.
Vivek Subbiah, MD, University of Texas, overviews the FIGHT-101 trial on pemigatinib, a selective FGFR 1-3 inhibitor, which targets mutations across a variety of tumor types.
Vivek Subbiah, MD, University of...
04/01/2022
Oncology
Dr Azab
Videos
02/16/2022
Kareem Azab, PhD, discusses 3D tissue-engineered bone marrow as a tool to predict patient responses to therapy for MM.
Kareem Azab, PhD, discusses 3D tissue-engineered bone marrow as a tool to predict patient responses to therapy for MM.
Kareem Azab, PhD, discusses 3D...
02/16/2022
Oncology
Videos
02/13/2025
Mohamed S. Abdelbaki, MD, discusses the course of treatment he would take for a patient with BRAF V600E-mutated pediatric low-grade glioma.
Mohamed S. Abdelbaki, MD, discusses the course of treatment he would take for a patient with BRAF V600E-mutated pediatric low-grade glioma.
Mohamed S. Abdelbaki, MD,...
02/13/2025
Oncology
Mateo Mejia Saldarriaga, MD
Videos
02/12/2025
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD discusses the latest trial data on the utilization of various CAR T-cell therapies for patients with relapsed/refractory multiple myeloma at the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium.
Mateo Mejia Saldarriaga, MD...
02/12/2025
Oncology
Melissa Alsina, MD
Conference Coverage
02/12/2025
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses quadruplet therapy with the goal of achieving MRD for patients who are transplant-eligible with newly diagnosed multiple myeloma.
Melissa Alsina, MD discusses...
02/12/2025
Oncology
Anna-Dorothea Wagner, MD
Conference Coverage
02/11/2025
Anna-Dorothea Wagner, MD, discusses results from the INNOVATION trial which found the addition of trastuzumab to FLOT chemotherapy did not improve survival outcomes for patients with HER2-positive gastric cancers.
Anna-Dorothea Wagner, MD, discusses results from the INNOVATION trial which found the addition of trastuzumab to FLOT chemotherapy did not improve survival outcomes for patients with HER2-positive gastric cancers.
Anna-Dorothea Wagner, MD,...
02/11/2025
Oncology
Marwan Fakih, MD
Conference Coverage
02/11/2025
Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.
Marwan Fakih, MD, discusses study results which identified the optimal dosage of botensilimab and balstilimab for patients with refractory microsatellite stable colorectal cancer without liver metastases.
Marwan Fakih, MD, discusses...
02/11/2025
Oncology
Matthew Davids, MD, MMSc
Videos
02/09/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Matthew Davids, MD, MMSc, discusses considerations for BTK inhibitor resistance and mutations in the treatment of patients with CLL.
At the 2025 Lymphoma, Leukemia &...
02/09/2025
Oncology
KOL Roundtable
Videos
02/08/2025
In part 4 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss innovative myelofibrosis treatments and exciting new data on future therapies with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 4 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss innovative myelofibrosis treatments and exciting new data on future therapies with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 4 of this expert...
02/08/2025
Oncology
Videos
02/08/2025
In part 3 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss therapies for patients with relapsed or refractory myelofibrosis with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 3 of this expert roundtable covering the latest updates in myelofibrosis, Firas El Chaer, MD, discuss therapies for patients with relapsed or refractory myelofibrosis with Raajit K Rampal, MD, and Lindsay A M Rein, MD.
In part 3 of this expert...
02/08/2025
Oncology
Sangeetha Venugopal, MD
Videos
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Sangeetha Venugopal, MD, discusses considerations for utilizing menin inhibitor therapy for patients with relapsed AML.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
Gabriela Hobbs, MD
Videos
02/08/2025
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Gabriela Hobbs, MD, discusses innovative therapies and strategies for treating patients with myeloproliferative neoplasms.
At the 2025 Lymphoma, Leukemia & Myeloma Winter Symposium, Gabriela Hobbs, MD, discusses innovative therapies and strategies for treating patients with myeloproliferative neoplasms.
At the 2025 Lymphoma, Leukemia &...
02/08/2025
Oncology
OLN

FGFR

ALIASES

Fibroblast growth factor receptor

Fibroblast growth factor receptors (FGFR) are a gene family of receptor tyrosine kinases that are differentially expressed in a tissue-specific manner throughout development and into adulthood. The signaling members identified in vertebrates are the homologs FGFR1, FGFR2, FGFR3, and FGFR4.1 They are involved in biological processes such as cell growth, migration, differentiation, survival, and apoptosis and are essential for embryonic and neural development, skeletal and organ formation, and adult tissue homeostasis.2 Altered FGFRs have been identified in cancer cells and therefore, FGFR targeting reagents may inhibit cancer growth.3

Expression Percentages per Cancer Type

Cholangiocarcinoma
30%
Urothelial Carcinoma
30%

Resources

FDA Approval
01/20/2024
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1 of the BLC3001 study, the FDA has approved erdafitinib for patients with locally advanced/metastatic urothelial carcinoma harboring FGFR3 alterations.
Based on results from cohort 1...
01/20/2024
Oncology
News
12/19/2023
Final results from the phase 2 FIGHT-201 trial found pemigatinib demonstrated clinical activity and tolerable safety among patients with unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations.
Final results from the phase 2 FIGHT-201 trial found pemigatinib demonstrated clinical activity and tolerable safety among patients with unresectable or metastatic urothelial carcinoma with FGFR3 genetic alterations.
Final results from the phase 2...
12/19/2023
Oncology
News
12/01/2023
According to the phase 3 THOR trial, erdafitinib prolonged overall survival among patients with FGFR-altered metastatic urothelial carcinoma who had previously received treatment with anti–PD-1/L1 agents, compared with chemotherapy.
According to the phase 3 THOR trial, erdafitinib prolonged overall survival among patients with FGFR-altered metastatic urothelial carcinoma who had previously received treatment with anti–PD-1/L1 agents, compared with chemotherapy.
According to the phase 3 THOR...
12/01/2023
Oncology
News
03/09/2022
Results of the ongoing FIGHT-203 trial show pemigatinib for FGFR1-mutant myeloid and lymphoid neoplasms may be a bridge for HSCT or a long-term treatment option for those ineligible for transplant.
Results of the ongoing FIGHT-203 trial show pemigatinib for FGFR1-mutant myeloid and lymphoid neoplasms may be a bridge for HSCT or a long-term treatment option for those ineligible for transplant.
Results of the ongoing FIGHT-203...
03/09/2022
Oncology
News
02/25/2022
Erdafitinib continues to show efficacy with longer follow-up for patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations.
Erdafitinib continues to show efficacy with longer follow-up for patients with locally advanced or metastatic urothelial carcinoma and prespecified FGFR alterations.
Erdafitinib continues to show...
02/25/2022
Oncology
News
02/23/2022
Results from the FIGHT-101 trial confirm pemigatinib was safe and tolerable in patients with FGFR mutant hematologic malignancies. These findings prompted phase 2/3 trials in multiple tumors that will benefit from this precision therapy.
Results from the FIGHT-101 trial confirm pemigatinib was safe and tolerable in patients with FGFR mutant hematologic malignancies. These findings prompted phase 2/3 trials in multiple tumors that will benefit from this precision therapy.
Results from the FIGHT-101 trial...
02/23/2022
Oncology
Conference Coverage
02/13/2025
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion study demonstrated that the addition of mevrometostat to enzalutamide improved outcomes compared to enzalutamide alone among patients with metastatic castration-resistant prostate cancer.
Results from a dose-expansion...
02/13/2025
Oncology
Conference Coverage
02/13/2025
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3 TALAPRO-2 trial demonstrated that first-line talazoparib plus enzalutamide significantly improved survival for patients with metastatic castration-resistant prostate cancer unselected for HRR gene alterations.
Results from the phase 3...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...
According to results from the TALAPRO-2 trial, the addition of talazoparib to enzalutamide significantly improved the overall survival among patients with homologous recombination repair-deficient castration-resistant prostate cancer in the...
According to results from the...
02/13/2025
Oncology
Conference Coverage
02/13/2025
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of...
02/13/2025
Oncology
News
02/13/2025
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a phase 1/1b trial, the addition of telisotuzumab vedotin to osimertinib demonstrated promise among patients with advanced, non-squamous EGFR-mutated non-small cell lung cancer with c-Met protein overexpression.
According to results from a...
02/13/2025
Oncology
Conference Coverage
02/13/2025
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results from a phase 2 study, first-line lenvatinib plus tislelizumab demonstrated promising efficacy and safety among patients with advanced fumarate hydratase-deficient renal cell carcinoma.
According to preliminary results...
02/13/2025
Oncology
FDA Approval
02/12/2025
On February 11, 2025, the US Food and Drug Administration approved brentuximab vedotin with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-Cell lymphoma.
On February 11, 2025, the US Food and Drug Administration approved brentuximab vedotin with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-Cell lymphoma.
On February 11, 2025, the US...
02/12/2025
Oncology
FDA Approval
02/11/2025
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase 2b ReNeu trial, the FDA has approved mirdametinib for adult and pediatric patients 2 years of age and older who have neurofibromatosis type 1-associated symptomatic plexiform neurofibromas not amenable to...
ased on results from the phase...
02/11/2025
Oncology
News
02/11/2025
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared outcomes among pediatric and adult patients with central nervous system tumors with NTRK gene fusion based on tumor histology and type of treatment.
A retrospective study compared...
02/11/2025
Oncology
News
02/11/2025
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of thyroid cancer among patients receiving GLP-1RA therapy, there was an increased risk within the first year of GLP-1RA initiation when compared with 3 other diabetes drugs.
Despite a low absolute risk of...
02/11/2025
Oncology

Podcasts

Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
03/07/2024

Featured Petros Grivas, MD, PhD

Featured Petros Grivas, MD, PhD ...
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares results from the phase 2 TROPHY-U-01 study evaluating sacituzumab govetican plus pembrolizumab among patients with metastatic urothelial carcinoma following progression on platinum-chemotherapy.
Petros Grivas, MD, PhD, shares...
03/07/2024
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine – UCLA, Los Angeles, CA
Podcasts
02/16/2023
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she would treat a patient with early stage HER2-positive breast cancer.
Sara Hurvitz, MD, shares how she...
02/16/2023
Oncology
Michael Hall, MD, Fox Chase Cancer Center
Podcasts
12/20/2022
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his presentation from the 2022 Great Debates & Updates in Gastrointestinal Malignancies virtual meeting, on genetic testing for gastrointestinal cancers.
Michael Hall, MD, reviews his...
12/20/2022
Oncology
Petros Grivas, MD, PhD, Fred Hutchinson Cancer Center
Podcasts
11/15/2022
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares how he would treat a patient who presented with a new diagnosis of metastatic urothelial cancer and progressed after completing a gemcitabine-cisplatin chemotherapy regimen.
Petros Grivas, MD, PhD, shares...
11/15/2022
Oncology
OLN favicon
Podcasts
07/29/2022
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses findings from an analysis exploring the association between the BRCAness phenotype and response to platinum-based chemotherapy among patients with intrahepatic cholangiocarcinoma.
Margherita Rimini, MD, discusses...
07/29/2022
Oncology
Ruth He, MD, Lombardi Comprehensive Cancer Center
Podcasts
07/22/2022
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings from a subgroup analysis which evaluated outcomes of patients with biliary tract cancer receiving durvalumab plus chemotherapy by primary tumor location: intrahepatic or extrahepatic cholangiocarcinoma or...
Ruth He, MD, discusses findings...
07/22/2022
Oncology
Arndt Vogel, MD, Hannover Medical School
Podcasts
07/14/2022
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results from the phase 2, FIGHT-202 trial which evaluated pemigatinib in patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Arndt Vogel, MD, shares results...
07/14/2022
Oncology
Petros Grivas, MD, Fred Hutchinson Cancer Center
Podcasts
06/22/2022
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares results from the phase 2 TROPHY-U-01 trial evaluating the sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer who progressed after platinum-based regimens.
Petros Grivas, MD, shares...
06/22/2022
Oncology
Robert Jones, MD
Podcasts
06/21/2022
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results and insights from the phase 2 ATLANTIS trial, evaluating maintenance cabozantinib following platinum-based chemotherapy for patients with metastatic urothelial carcinoma.
Robert Jones, MD, shares results...
06/21/2022
Oncology
David O'Malley
Podcasts
06/20/2022
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast series, David O'Malley, MD, Ohio State University, discusses strategies for overcoming PARP inhibitor and platinum resistance in patients with ovarian cancer.
In part 2 of this 2-part podcast...
06/20/2022
Oncology

Interactive

Quiz
04/06/2022
True or false: FGFR3 mutations are seen in bladder cancer.
True or false: FGFR3 mutations are seen in bladder cancer.
True or false: FGFR3 mutations...
04/06/2022
Oncology
Test Your Knowledge
02/25/2022
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101 trial revealed pemigatinib is unsafe for patients with FGFR mutant hematologic malignancies.
True or false: The FIGHT-101...
02/25/2022
Oncology
Test Your Knowledge
02/25/2022
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a pan-FGFR TKI, showed long-term efficacy for advanced urothelial carcinoma.
True or false: Erdafitinib, a...
02/25/2022
Oncology
Quiz
02/10/2025
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate equivalent to or better efficacy than platinum rechallenge among patients with platinum-sensitive small cell lung cancer who experience relapse after treatment with platinum-based therapy?
Did lurbinectedin demonstrate...
02/10/2025
Oncology
Quiz
02/07/2025
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine improve invasive disease-free survival compared to trastuzumab in patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy?
Did trastuzumab emtansine...
02/07/2025
Oncology
Quiz
01/22/2025
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of trilaciclib prior to chemotherapy reduce the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer?
Did the administration of...
01/22/2025
Oncology
Quiz
12/20/2024
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line lenvatinib plus pembrolizumab significantly improved survival compared to lenvatinib plus chemotherapy for patients with mismatch repair-proficient advanced or recurrent endometrial cancer? Take our quiz to find out!
Do you know if first-line...
12/20/2024
Oncology